Infection Clinical Trial
Official title:
Myelodysplasic Syndromes and Risk Factors for Infection : A Case / Control Study
Myelodysplastic Syndromes (MDS) are characterized by quantitative and qualitative bone
marrow failure and by a disorder of the medullary production which is a pre-leukemic state
which can evolve into acute myeloid leukemia.
The risk of leukemic transformation is estimated by the score IPSS (International Prognostic
Score System). We distinguish the MDS of low risk (IPSS<1) and those of high risk of
leukemic transformation (IPSS=1,5).
Besides the risk of leukemic transformation, MDS much be complicated of infections which
could be life-threatening.
The risk of developing first infection after the diagnosis of MDS of high risk is probably
influenced by anamnestic (disease duration, comorbidities), clinical (veinous central
catheter, previous hospitalization), biological (neutropenia, lymphopenia, serum ferritin)
and therapeutics (demethylating agent, lenalidomide, erythropoietin, G-CSF, transfusions,
anti-infectious preventive treatment) factors. Their identification will allow for improved
targeting of the population which is is likely to benefit from anti-infective prophylaxis
Primary objective is to identify risk factors associated with first acute episode of
infection in patients with MDS, by comparing index cases and matched control cases who did
not develop infection episode since diagnosis.
Secondary objectives are to explore nature and severity of infectious episodes, number of
recurrences during 1 year of follow up and survival at 6 and 12 months
- 160 couples (Case / Control)
- Pairing according to age (+/- 5 years), sex and medical consultation date (+/-15 days)
- Follow up at M3, M6, M9 and M12
- Study duration : 24 months
- Inclusion duration : 12 months
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A | |
Recruiting |
NCT01085669 -
Infection Rate of Vertical Expandable Prosthetic Titanium Rib Implants (VEPTR)
|
N/A |